Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEONEC D19-01 neoadjuvant platinum-etoposide study in localized digestive neuroendocrine carcinoma
2024-515603-19-01Phase 2Authorised
- Sponsor
- GERCOR
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, etoposide and carboplatin in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by GERCOR. Primary endpoints: 12-month relapse-free survival in treated patients and 12-month relapse-free survival after surgery. Planned start Jan 2025; status: authorised.
02
Drugs
cisplatinetoposidecarboplatin
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on 2024-515603-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515603-19-01.